Please login to the form below

Kite

This page shows the latest Kite news and features for those working in and with pharma, biotech and healthcare.

Kite’s CAR-T therapies recommended by NICE for certain blood cancers

Kite's Yescarta (axicabtagene ciloleucel) has been recommended for adults with diffuse large B‑cell lymphoma (DLBCL) that returns within a year of, or is resistant to, first-line chemoimmunotherapy. ... Overall, Kite’s therapies could benefit up to

Latest news

Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer

Kite, a Gilead company, has reported positive three-year follow-up results from an ongoing study of its CAR T-cell therapy Tecartus (brexucabtagene autoleucel) in relapsed/refractory B-cell acute ... Results from the analysis of Kite’s phase 1/2 ZUMA-3
Kite and Arcellx close multiple myeloma collaboration agreement

Kite, a Gilead Company, and Arcellx have announced the closing of their collaboration agreement to jointly develop and commercialise Arcellx’s late-stage candidate to treat relapsed or refractory multiple myeloma. ... Cell therapy has proven it can
Gilead’s CAR-T cell therapy recommended by NICE for lymphoma

Gilead Science and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) to treat certain forms of lymphoma.
Kite announces acquisition of Tmunity Therapeutics in latest agreement

As part of Kite’s acquisition, the Tmunity founders will become senior scientific advisors for Kite. ... The deal is expected to close in the first quarter of 2023, and after closing, Tmunity’s employees will join Kite.
Kite and Arcellx partner to develop and commercialise multiple myeloma candidate

Beyond the US, Kite will commercialise the product and Arcellx will receive royalties on sales. ... Kite will assume responsibility for the development and commercialisation costs for any product under the collaboration that is not co-commercialised.

More from news
Approximately 31 fully matching, plus 73 partially matching documents found.

Latest Intelligence

Sourcing R&D innovation: why pharma companies need to evolve their business models

and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
Drug launches to watch in 2019

1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene
Deal Watch October 2018

Gilead’s subsidiary, Kite, has agreed a deal for a research collaboration with HiFiBiO Therapeutics, the Hong Kong-based company which is working on the discovery of therapeutic antibodies through single
The European Medicines Agency: PRIME’d for access?

Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
Bluebird Bio: on the cusp of a gene therapy revolution

drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... Spark has signed a marketing deal with Novartis in Europe, which means the big pharma company will set the

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

New hires at Abbott, Kite and Arrakis Therapeutics

Kite . Kite, a Gilead company, has appointed two new additions to its leadership team. ... Also joining Kite is Ken Takeshita, who has been appointed as global head of clinical development.
PureTech Health appoints new chief financial officer

Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma
Gilead Sciences promotes Dr Alessandro Riva to EVP, oncology therapeutics

Dr Riva joined the biopharmaceutical group in January 2017, and his previous role saw him take responsibility in expanding Gilead’s oncology programme with the recent acquisition of Kite Pharma. ... John McHutchinson, executive vice president, clinical
Sanofi biologics supply VP joins Kite Pharma

Dr Jian Irish becomes senior vice president of supply chain. California-based Kite Pharma has appointed Dr Jian Irish as senior vice president of supply chain. ... Tim Moore, executive vice president of technical operations at Kite Pharma, said: “Jian
Former Roche CEO and chairman joins Arix Bioscience

He is currently chairman of Diageo, a consumer goods company, and a non-executive director of Chugai P harmaceuticals, Citigroup and Kite Pharma.

More from appointments
Approximately 4 fully matching, plus 6 partially matching documents found.

Latest from PMHub

Understanding the evolving CAR-T market

Big pharma also wanted a slice of the action. Aggressive deal-making quickly became central to the rise of CAR-T, with Gilead acquiring Kite Pharma for a mammoth $11.9bn
Training the next generation of biotech leaders

In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’s Yescarta in October.
How do you define a biotech company?

This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where